The prevalence of obesity has increased considerably in the last few decades.
Pathophysiological changes in obese patients lead to pharmacokinetic (PK) and …

As obesity continues to increase in prevalence throughout the world, it becomes important to
explore the effects that obesity has on antimicrobial disposition. Physiologic changes in …

Highlights•A singular approach to antimicrobial dose selection in obese patients is not
feasible.•Total body weight based dosing risks over exposure and toxicity in obese …

Limited data exist for appropriate drug dosing in obese children. This comprehensive review
summarizes pharmacokinetic (PK) alterations that occur with age and obesity, and these …

Five hundred million adults meet the current definition of obesity worldwide. This high global
prevalence of obesity offers unique challenges to the selection of the optimal antimicrobial …

As the prevalence of obesity continues to rise significantly worldwide, an increasing number
of overweight patients are expected to present to hospital with various pathological …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

Background Altered pharmacokinetics in obese patients raise concerns over worse clinical
outcomes. This study assessed whether obese patients receiving a β-lactam have worse …

Severe sepsis and septic shock can alter the pharmacokinetics of broad-spectrum β-lactams
(meropenem, ceftazidime/cefepime, and piperacillin-tazobactam), resulting in inappropriate …

Introduction Ceftazidime is used for the treatment of many bacterial infections, including
severe P. aeruginosa infections. Like other beta-lactams, inter-individual variability in …